Imidazolopiperazines: Lead Optimization of the Second-Generation Antimalarial Agents

Author:

Nagle Advait1,Wu Tao1,Kuhen Kelli1,Gagaring Kerstin1,Borboa Rachel1,Francek Caroline1,Chen Zhong1,Plouffe David1,Lin Xuena2,Caldwell Christopher2,Ek Jared1,Skolnik Suzanne2,Liu Fenghua2,Wang Jianling2,Chang Jonathan1,Li Chun1,Liu Bo1,Hollenbeck Thomas1,Tuntland Tove1,Isbell John1,Chuan Tiffany1,Alper Philip B.1,Fischli Christoph34,Brun Reto34,Lakshminarayana Suresh B.5,Rottmann Matthias34,Diagana Thierry T.5,Winzeler Elizabeth A.1,Glynne Richard1,Tully David C.1,Chatterjee Arnab K.1

Affiliation:

1. Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121, United States

2. Novartis Institute for Biomedical Research, Preclinical Profiling Group, Cambridge, Massachusetts

3. Swiss Tropical and Public Health Institute, Parasite Chemotherapy, CH-4002 Socinstrasse 57, CD-4002 Basel, Switzerland

4. University of Basel, CH-4003 Basel, Switzerland

5. Novartis Institute for Tropical Diseases, 10 Biopolis Road, 05-01 Chromos, Singapore-138670

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3